November 21, 2013
Takeda Pharmaceutical said on November 19 that it has started enrolling patients in Japan in an ongoing global PIII clinical study for MLN9708 (ixazomib citrate), a novel oral proteasome inhibitor, after the compound demonstrated efficacy in its domestic PI trial...read more